The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
2d
MarketBeat on MSNWill Eli Lilly Stock Keep Climbing? Q2 Trial Results Are CrucialEli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...
Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Here are 5 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years.
Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...
Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results